Novartis AG NOVN
SIX · Switzerland · Health Technology
CHF 118.18-1.78 (-1.48%)
Market open· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Investing.com -- Deutsche Bank on Thursday named its top European stock picks for the next 12 months, adding six new names and dropping six from its third-quarter list.
AI-driven discovery, streamlined approvals and partnerships are accelerating drug repurposing, creating opportunities in oncology, rare, neurodegenerative and infectious diseases.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Drug Repurposing Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global drug repurposing market was valued at US$29.4 billion in 2024 and is projected to reach US$37.3 billion by 2030, expanding at a compound annual growth ra
The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.Dublin, Sept. 30, 2026
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.